Martin H. Voss, MD

Dr. Voss and Dr. Serzan continue their discussion of treatment strategies for non-clear cell renal cell carcinoma (RCC), focusing on evidence for IO-TKI and IO-IO approaches across different histologic subtypes.

Dr. Voss and Dr. Serzan turn to non-clear cell renal cell carcinoma (RCC), highlighting the heterogeneity of these tumors and the ongoing unmet need for more effective treatment strategies.

Dr. Voss and Dr. Serzan discuss how disease burden and the location of metastases can influence first-line treatment selection in advanced renal cell carcinoma (RCC).

Dr. Voss and Dr. Serzan discuss factors that inform first-line treatment selection in advanced clear cell renal cell carcinoma (RCC) among established immune checkpoint inhibitor-based regimens.

Dr. Voss and Dr. Serzan discuss how the practical considerations surrounding cytoreductive nephrectomy can differ depending on the first-line regimen used in advanced renal cell carcinoma (RCC).

Dr. Serzan discusses the clinical significance of response depth in advanced renal cell carcinoma (RCC), highlighting evidence from the CLEAR trial that greater tumor reduction, particularly complete responses, is associated with more favorable long-term outcomes.

Dr. Voss and Dr. Serzan discuss the evolution of first-line treatment patterns in advanced renal cell carcinoma (RCC) over the past several years, highlighting the transition from tyrosine kinase inhibitor monotherapy toward immune-based combination regimens.

Dr. Martin Voss and Dr. Michael Serzan introduce the evolving treatment landscape for advanced renal cell carcinoma (RCC), emphasizing the importance of individualized first-line treatment selection.

Martin Voss, MD, reviews results from the phase 3 LITESPARK-011 trial presented at the 2026 ASCO Genitourinary Cancers Symposium, highlighting the progression-free survival benefit and safety profile of belzutifan plus lenvatinib compared with cabozantinib in patients with previously treated metastatic clear cell renal cell carcinoma.

Martin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.

Martin H. Voss, MD, discusses a trial of cabozantinib plus nivolumab in renal cell carcinoma and how it relates to updated NCCN treatment guidelines.

Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

Martin Voss, MD, elaborates on the impact of the KEYNOTE-564 trial and its recently presented data on the management of renal cell carcinoma, highlighting how these findings have influenced treatment decisions and patient care strategies.

Wenxin (Vincent) Xu, MD, presents the findings from the phase 3 CONTACT-03 trial, which compared the efficacy of atezolizumab in combination with cabozantinib versus cabozantinib alone in patients with inoperable advanced renal cell carcinoma who had previously received immune checkpoint inhibitor treatment.

The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit.

Pedro Barata, MD, MSc, prompts the panel to share their opinions on which of the discussed clinical trials they find most promising and likely to influence clinical practice in the treatment of renal cell carcinoma.

Elizabeth Wulff-Burchfield, MD, facilitates a conversation about several clinical trials, such as STELLAR-001 and KEYNOTE-426, which investigate various treatment approaches for renal cell carcinoma (RCC).

Martin H. Voss, MD, presents data supporting the use of various combination regimens in the frontline treatment of renal cell carcinoma (RCC), focusing on the pivotal trials such as CheckMate 214, KEYNOTE 426, and the CLEAR trial, emphasizing their respective efficacy, safety, and overall impact on the current treatment landscape for RCC patients.

Moshe Ornstein, MD, presents a detailed clinical case study of a 61-year-old male patient diagnosed with renal cell carcinoma.

Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.